- Conditions
- Multiple Sclerosis, Low Bone Density
- Interventions
- Copaxone, Interferon-beta 1a, Interferon-beta 1b
- Drug
- Lead sponsor
- Nancy Hammond, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 118
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
- Procedure · Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
- Drug · Device
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more
- Conditions
- Multiple Sclerosis
- Interventions
- Anesthetic Topical Adhesive Synera
- Drug
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Interferon beta-1b, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1991
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois
- Conditions
- Multiple Sclerosis
- Interventions
- single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
- Device · Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- Avonex
- Drug
- Lead sponsor
- Trinity Health Of New England
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
- Drug
- Lead sponsor
- Revalesio Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
- Conditions
- Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Not listed
- Lead sponsor
- Providence Multiple Sclerosis Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Betaferon/Betaseron
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
- Conditions
- Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
- Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Covid19
- Interventions
- IFN beta-1a, Dexamethasone
- Drug
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
- Drug · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Betaseron (Interferon beta-1b, BAY86-5046)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more
- Conditions
- Multiple Sclerosis
- Interventions
- Avonex and Topamax
- Drug
- Lead sponsor
- Multiple Sclerosis Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Interferon beta 1-a, glatiramer acetate, placebo
- Drug · Other
- Lead sponsor
- Fred Lublin
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 1,008 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Malignant Solid Tumour
- Interventions
- VSV-IFNβ-NIS, VSV-IFNβ-NIS and avelumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Minneapolis, Minnesota • Columbus, Ohio + 3 more
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
- Interventions
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Memgen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Alemtuzumab, Interferon beta-1a
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 36
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more